Account
Insider Insights
07.03.2024
EU releases draft act on Joint Clinical Assessment...

Consultation launched on EU draft Regulation for joint clinical assessments, seeking feedback to imp...

Read more
Insider Insights
23.02.2024
New Committee Paves the Way for Biosimilar Substit...

ANSM establishes a Temporary Scientific Committee to promote biosimilar substitution, enhancing pati...

Read more
Insider Insights
22.02.2024
Nordic Pharmaceutical Forum develops new website t...

New website provides regular updates on NLF's work, addresses challenges, and showcases collaboratio...

Read more
Insider Insights
16.02.2024
Biosimilar Switching in Germany from March 15, 202...

New biosimilar switching regulations prioritise cost-effective options and discount agreements, imp...

Read more
Insider Insights
14.02.2024
NICE update: What manufacturers need to know about...

Our analysts explore NICE's integration of tech appraisals into treatment guidelines for to enable o...

Read more
Insider Insights
06.02.2024
Confidential rebates are raising concerns in Germa...

Proposed changes in Germany's pharma strategy suggest replacing publicly listed AMNOG rebates with c...

Read more
Insider Insights
30.01.2024
AIFA regulatory overhaul marks milestone in Pharma

AIFA's restructuring in Italy aims to streamline drug approval, replacing committees and introducing...

Read more
Insider Insights
30.01.2024
Financing of new orphan drugs in Spain increases i...

Spain seeks to enhance financing for orphan drug access, signalling a push for better timelines and ...

Read more
Insider Insights
30.01.2024
NICE recommends Talazoparib for advanced breast ca...

NICE set to endorse talazoparib for adults with BRCA 1 or 2 mutated HER2-negative locally advanced o...

Read more
Insider Insights
30.01.2024
AML treatment Tibsovo earns key rating in Germany

Tibsovo (ivosidenib) has been granted a major additional benefit rating for its use as a first-line ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.